(https://www.cnbc.com/2026/08/24/biotech-stocks-are-breaking-out-how-josh-brown-is-trading-them.html) this week, but the composition of that rally masks a sector in structural trouble. AZN posted a net margin with in revenue — solid baseline, but the 4Q sequence (58.7B, 28.0B, 54.1B, 12.9B) shows volatile execution and no clear growth narrative.

Research these companies